학술논문
PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL
Document Type
Article
Author
Source
In: European Journal of Haematology . (European Journal of Haematology, August 2023, 111(2):191-200)
Subject
Language
English
ISSN
16000609
09024441
09024441